61results about How to "Less toxic" patented technology

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Disclosed herein are teeth whitening compositions generally including an oxidizing agent (e.g., a peroxide), and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B, Eosin Y, or Erythrosine B). Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.

ACE-2 modulating compounds for the treatment of body weight disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

Disclosed herein are compositions and methods useful for the in vivo delivery bis(thiohydrazide amides), encased in a polymeric biocompatible shell.

The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death.

The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and / or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and / or cancerous diseases or conditions In one embodiment, the condition is mediated by MIF (macrophage migration inhibiting factor).

The invention features methods, compositions, and kits for treating a musculoskeletal disorder, e.g., osteoarthritis, or pain, fatigue, tenderness, impairment in mobility, soft tissue swelling, or bony swelling associated therewith, by administering to a patient diagnosed with or at risk of developing such pain, fatigue, tenderness, impairment in mobility, soft tissue swelling, or bony swelling a tetra-substituted pyrimidopyrimidine, e.g., dipyridamole, or an adenosine activity upregulator, in combination with one or more additional agents. The invention further features methods, compositions, and kits for treating a patient diagnosed with or at risk of developing a musculoskeletal disorder by administering to the patient a tetra-substituted pyrimidopyrimidine or an adenosine activity upregulator in combination with one or more additional agents.

A multi-junction photovoltaic cell device. The device includes a lower cell and an upper cell, which is operably coupled to the lower cell. In a specific embodiment, the lower cell includes a lower glass substrate material, e.g., transparent glass. The lower cell also includes a lower electrode layer made of a reflective material overlying the glass material. The lower cell includes a lower absorber layer overlying the lower electrode layer. In a specific embodiment, the absorber layer is made of a semiconductor material having a band gap energy in a range of Eg=0.7 to 1 eV, but can be others. In a specific embodiment, the lower cell includes a lower window layer overlying the lower absorber layer and a lower transparent conductive oxide layer overlying the lower window layer. The upper cell includes a p+ type transparent conductor layer overlying the lower transparent conductive oxide layer. In a preferred embodiment, the p+ type transparent conductor layer is characterized by traversing electromagnetic radiation in at least a wavelength range from about 700 to about 630 nanometers and filtering electromagnetic radiation in a wavelength range from about 490 to about 450 nanometers. In a specific embodiment, the upper cell has an upper p type absorber layer overlying the p+ type transparent conductor layer. In a preferred embodiment, the p type conductor layer made of a semiconductor material has a band gap energy in a range of Eg=1.6 to 1.9 eV, but can be others. The upper cell also has an upper n type window layer overlying the upper p type absorber layer, an upper transparent conductive oxide layer overlying the upper n type window layer, and an upper glass material overlying the upper transparent conductive oxide layer.

The invention provides compositions derived from brown-rot fungi that are suitable for use in bioremediation and similar applications where it is desirable to transform a target compound, often a toxic organic compound, into a different compound or compounds having more acceptable properties. The compositions are suitable for treating aqueous solutions or suspensions to reduce the amount of an undesired organic compound present, usually as one step in a treatment process to render the solution or suspension more suitable for environmental release. The invention also provides improved methods for growing fungal cultures for production of culture fluids.

The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceutical agent conjugates are provided.

A proteomic screening method for anaerobic-specific and expression-effective promoter, and a method of specially delivering and selectively stably expressing target gene in anaerobic tissue by an alcohol dehydrogenase promoter and uses thereof. The latter comprises an anaerobically-induced alcohol dehydrogenase promoter which is used as target gene promoter, anaerobic target bacteria and low copy number plasmid. Therefore, the target gene can be specially and highly expressed under hypoxia condition in vivo or in vitro. The selective gene expression which is driven by the alcohol dehydrogenase promoter in anaerobic tissue can be used as gene therapy method to treat anaerobic tissue disease including tumor, or to prepare anti-tumor drug.

The invention relates to a coal asphalt material for paving a high-grade road and a preparation method of the coal asphalt material. The existing preparation method of the coal asphalt has the defects of low coal asphalt utilization rate, large modifier dosage, high cost, complicated process, poor material stability and the like. The method disclosed by the invention comprises the following steps: taking mid-low temperature coal asphalt, and hotly melting to obtain a sticky substance; adding a plasticizer, and adding anhydride compounds and a lewis acid after agitating; adding polyethylene glycol after heating reaction, and then dewatering after reacting again, so as to obtain the coal asphalt material for paving the high-grade road. By adopting the process, the condensation phenomenon of the coal asphalt at high temperature is removed, and the low-temperature fragility and the cracking property of the coal asphalt are changed, meanwhile, the toxic properties of polycyclic aromatic hydrocarbon are greatly reduced, the additional value of the coal asphalt is increased, and favorable economic benefits can be generated.

The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmaceutical agent conjugates are provided.

The invention provides Zn-chelating compounds that are molecularly engineered to bind to a specific target sequence in a protein of interest. The Zn2+ ion is far less toxic and promiscuous than nickel and therefore provides an attractive alternative to Ni-based labeling systems. Invention Zn-chelating compounds also do not require oxidizable thiols and therefore can be used in non-reducing environments such as the surface of living cells. In addition, the target sequence is genetically encodable and requires incorporation of only a few amino acids, unlike fusions to fluorescent proteins such as GFP.

The present invention provides methods for preparing complexed diaryl boronic acids from alkyl diarylborinates.

The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).

The invention relates to N,N-dimethyl-4-cyclohexylaminomethylcyclohexane as well as a preparation method and application thereof. The method comprises the following step of preparing the N,N-dimethyl-4-cyclohexylaminomethylcyclohexane by utilizing a byproduct deammoniated light component in an HMDA (Hexamethylene Diamine) reaction process, formaldehyde and hydrogen gas under the action of a catalyst and under certain temperature and pressure through hydrogenation and methylation. After being purified, the obtained N,N-dimethyl-4-cyclohexylaminomethylcyclohexane can be used as a polyurethane catalyst; effective utilization of an HMDA byproduct is realized and polyurethane foam prepared from the N,N-dimethyl-4-cyclohexylaminomethylcyclohexane has the advantages of low odor, good physical properties and the like.

A synthetic route is provided to prepare poly(ω-hydroxycarboxylic acid) polymers via the ring-opening polymerization of ω-hydroxycarboxylic acid cyclic oligomers. The cyclic oligomers can be prepared directly from biorenewable sources, such as 3-hydroxypropionic acid. The method can be used to prepare high molecular weight polymers from the cyclic oligomers. Good molecular weight control can be obtained for both solution state and melt polymerizations.

The invention discloses medium-temperature silver-free copper-based brazing filler metal and a method for preparing the same. The medium-temperature silver-free copper-based brazing filler metal comprises, by weight, 4.0%-7.5% of P, 1.0%-15.0% of Sn, 0.5%-2.0% of Si, 0-1.0% of Sb, 0.3%-0.8% of B, 0.2%-1.0% of Ti, 0.2%-0.8% of Zr, 0-2.0% of Ni and the balance Cu. The medium-temperature silver-free copper-based brazing filler metal and the method have the advantages that the copper is used as a matrix for the medium-temperature silver-free copper-based brazing filler metal, diversified non-toxic and inexpensive metal elements are added into the copper, accordingly, characteristics of the medium-temperature silver-free copper-based brazing filler metal can be improved, and the medium-temperature silver-free copper-based brazing filler metal is excellent in braze welding technological characteristic; the medium-temperature silver-free copper-based brazing filler metal is prepared to obtain powder, has low melting temperature and is excellent in braze welding technological performance such as joint filling properties and wetting properties; the medium-temperature silver-free copper-based brazing filler metal prepared by the aid of the method can be flexibly used, is adaptive to weld joints in diversified shapes and is excellent in quality stability.